Aza-Morita–Baylis–Hillman Reaction with Vinyl-oxadiazoles: An Expeditious Approach to Access New Heterocyclic Arrangements

André Capretz-Agy; Fábio S. Fernandes; Manoel T. Rodrigues Jr.; Caroline Conti; Fernando Coelho

doi:10.1055/s-0039-1691497

Synlett, Table of Contents

Synlett 2020; 31(06): 622-626
DOI: 10.1055/s-0039-1691497

cluster

Aza-Morita–Baylis–Hillman Reaction with Vinyl-oxadiazoles: An Expeditious Approach to Access New Heterocyclic Arrangements

Authors

André Capretz-Agy
Fábio S. Fernandes∗
Manoel T. Rodrigues Jr.
Caroline Conti
Fernando Coelho ∗

Abstract

All articles of this category

Published as part of the ISySyCat2019 Special Issue

Abstract

In this communication, we disclosed a new aza-MBH reaction in which traditional nucleophilic partners of these reactions (e.g., acrylates, nitroolefins or enones) were replaced by vinyl-1,2,4-oxadiazoles. Thus, the aza-MBH reaction between 5-aryl-3-vinyl-1,2,4-oxadiazoles and N-sulfonylimines, catalyzed by the mixture DABCO/AcOH, provides a class of new adduct in yields varying from 31% up to 93% in reaction times from 30 minutes to 24 hours. Due to the biological activities and technological applications associated with the 1,2,4-oxadiazole motifs, this new class of heterocycles offers great synthetic and commercial potentiality.

Key words

vinyl-oxadiazoles - heterocycles - organocatalysis - Morita–Baylis–Hillman reaction - aza-Morita–Baylis–Hillman - nucleophilic partner

Full Text

References

References and Notes

1a Shi YL, Shi M. Eur. J. Org. Chem. 2007; 2905
1b Declerk V, Martinez J, Lamaty F. Chem. Rev. 2009; 109: 1
1c Drewes SE, Roos GH. P. Tetrahedron 1988; 44: 4653

2a Huang X, Xue J. J. Org. Chem. 2007; 72: 3965
2b Grychowska K, Kubica B, Drop M, Colacino E, Bantreil X, Pawłowski M, Martinez J, Subra G, Zajdel P, Lamaty F. Tetrahedron 2016; 72: 7462
2c Clary KN, Parvez M, Back TG. J. Org. Chem. 2010; 75: 3751
2d Grélaud S, Lusseau J, Massip S, Landais Y. Adv. Synth. Catal. 2017; 359: 2434
2e Basavaiah D, Rao AJ, Satyanarayana T. Chem. Rev. 2003; 103: 811
2f Basavaiah D, Rao PD, Hyma RS. Tetrahedron 1996; 52: 800

3 Perlmutter P, Teo CC. Tetrahedron Lett. 1984; 25: 5951

4a Shi M, Xu YM. Chem. Commun. 2001; 1876
4b Shi M, Xu YM, Zhao GL, Wu XF. Eur. J. Org. Chem. 2002; 3666

5 Shi M, Xu YM. Eur. J. Org. Chem. 2002; 696

6a Guan XY, Wei Y, Shi M. Eur. J. Org. Chem. 2010; 4098
6b Shen Y, Tang Q, Zhang C, Zhong W. Synlett 2012; 23: 741

7 Zhao GL, Huang JW, Shi M. Org. Lett. 2003; 5: 4737

8a Saunders LB, Cowen BJ, Miller SJ. Org. Lett. 2010; 12: 4800
8b Zhao GL, Shi M. J. Org. Chem. 2005; 70: 9975

9 Shi YL, Xu YM, Shi M. Adv. Synth. Catal. 2004; 346: 1220

10a Buscemi S, Pace A, Palumbo Piccionello A, Vivona N, Pani M. Tetrahedron 2006; 62: 1158
10b Back TG, Rankic DA, Sorbetti JM, Wulff JE. Org. Lett. 2005; 7: 2377
10c Clary KN, Back TG. Synlett 2007; 2995
10d Sorbetti JM, Clary KN, Rankic DA, Wulff JE, Parvez M, Back TG. J. Org. Chem. 2007; 72: 3326
10e Abermil N, Masson G, Zhu J. Org. Lett. 2009; 11: 4648

11 Wu Z, Zhou G, Zhou J, Guo W. Synth. Commun. 2006; 36: 2491
12 Chen J, Li J, Wang J, Li H, Wang W, Guo Y. Org. Lett. 2015; 17: 2214
13 Fernandes FS, Rodrigues MT, Zeoly LA, Conti C, Angolini CF. F, Eberlin MN, Coelho F. J. Org. Chem. 2018; 83: 15118
14 Watien F, Baker R, Engelstoff M, Herbert R, Macleod A, Knight A, Merchant K, Moseley J, Saunders J, Swain CJ, Wong E, Springer JP. J. Med. Chem. 1989; 32: 2282

15a Street LJ, Baker R, Castro JL, Chambers MS, Guiblin AR, Hobbs SC, Matassa VG, Reeve AJ, Beer MS, Middlemiss DN, Noble AJ, Stanton JA, Scholey K, Hargreaves RJ. J. Med. Chem. 1993; 36: 1529
15b Broadley KJ, Kelly DR. Molecules 2001; 6: 142
15c Csürös L. Ther. Hung. 1989; 37: 50
15d Ceyhan BB, Karakurt S. Respir. Med. 2002; 96: 61

16 Swain CJ, Baker R, Moseley J, Saunders J, Seward EM, Stevenson G, Kneen C, Beer M, Stanton J, Watling K. J. Med. Chem. 1991; 34: 140
17 Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, Tyers MB. Br. J. Pharmacol. 1988; 93: 985
18 Costall B, Domeney AM, Naylor RJ, Tyers MB. Br. J. Pharmacol. 1987; 92: 881

19a Pace A, Buscemi S, Piccionello AP, Pibiri I. Adv. Heterocycl. Chem. 2015; 116: 85
19b Pace A, Pierro P. Org. Biomol. Chem. 2009; 7: 4337

20a Ko D, Patel HA, Yavuz CT. Chem. Commun. 2015; 51: 2915
20b Agneeswari R, Tamilavan V, Song M, Kang JW, Jin SH, Hyun MH. J. Polym. Sci., Part A: Polym. Chem. 2013; 51: 2131

21a Joule JA, Mills K. Heterocyclic Chemistry, 5th ed. John Wiley & Sons; Chichester: 1990: 150
21b Cicchi S, Cordero FM, Giomi D. Prog. Heterocycl. Chem. 2007; 18: 288
21c Palumbo Piccionello A, Pace A, Buscemi S. Org. Lett. 2011; 13: 4749
21d Palumbo Piccionello A, Guarcello A, Buscemi S, Vivona N, Pace A. J. Org. Chem. 2010; 75: 8724
21e Zeng Z, Jin H, Xie J, Tian B, Rudolph M, Rominger F, Hashmi AS. K. Org. Lett. 2017; 19: 1020
21f Buscemi S, Pace A, Palumbo Piccionello A, Pibiri I, Vivona N, Giorgi G, Mazzanti A, Spinelli D. J. Org. Chem. 2006; 71: 8106
21g Strelnikova JO, Rostovskii NV, Starova GL, Khlebnikov AF, Novikov MS. J. Org. Chem. 2018; 83: 11232

22 Burns AR, Kerr JH, Kerr WJ, Passmore J, Paterson LC, Watson AJ. B. Org. Biomol. Chem. 2010; 8: 2777
23 Tata RR, Fu C, Kelley SP, Harmata M. Org. Lett. 2018; 20: 5723
24 Golushko AA, Khoroshilova OV, Vasilyev AV. J. Org. Chem. 2019; 84: 7495
25 General Procedure for the Synthesis of 1,2,4-Oxadiazole 1d²⁵ trans-β-Nitrostyrene 1 (2.0 mmol) was added to a mixture of TfOH (3.5 mL), CH₂Cl₂ (3.0 mL), and benzene (3.0 mmol) at –40 °C. After stirring at –40 °C for 1.5 h, the reaction mixture was poured at once into acrylonitrile (9.0 mmol) cooled to –30 °C. The resulting solution was heated to –20 °C and stirred at this temperature for 30 min, then quenched with water (30 mL) and extracted with CHCl₃ (3 × 30 mL). The combined organic phases were washed three times with water (40 mL) and dried with Na₂SO₄. The solvent was evaporated under the reduced pressure, and the residue was purified by chromatography column (hexane/EtOAc = 9:1); mp 53–55 °C. ¹H NMR (250 MHz, CDCl₃): δ = 7.53–7.27 (m, 10 H), 6.76 (dd, J = 17.7, 10.9 Hz, 1 H), 6.55 (dd, J = 17.7, 1.1 Hz, 1 H), 5.96 (dd, J = 10.9, 1.1 Hz, 1 H), 5.75 (s, 1 H). ¹³C NMR (63 MHz, CDCl₃): δ = 174.57, 172.11, 139.71, 128.92, 128.80, 128.73, 127.36, 120.68, 48.80. HRMS (ESI-TOF): m/z calcd for C₁₇H₁₅N₂O [M + H]⁺: 263.1179; found: 263.1189.
26 General Procedure for the Synthesis of Aza-Morita–Baylis–Hilman Adducts 3a–p In a 2mL flask equipped with a magnetic stir bar, oxadiazole (0.29 mmol), imine (0.32 mmol), and DABCO (34 mg, 0.30 mmol) were added sequentially. The atmosphere of the flask was exchanged for N₂, and then toluene (0.29 mL) and acetic acid (18 μL, 0.30 mmol) were added. The reaction was stirred at room temperature, and the time was specified for each substrate. After consumption of the starting material, as determined by TLC, the crude reaction was evaporated under reduced pressure. The residue was then purified by flash silica gel column chromatography (hexane/EtOAc = 9:1 to 7:3) to provide the aza-MBH adduct. N-{2-[3-(4-Methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-phenylprop-2-en-1-yl}benzenesulfonamide (3h) Purified by column chromatography (hexane/EtOAc = 8:2) to give 3h (100 mg, 0.22 mmol, 90%) as a white solid; mp 152–153 °C. ¹H NMR (500 MHz, CDCl₃): δ = 7.84 (d, J = 8.8 Hz, 2 H), 7.70 (d, J = 7.5 Hz, 2 H), 7.42 (t, J = 7.5 Hz, 1 H), 7.31 (t, J = 7.5 Hz, 2 H), 7.26–7.09 (m, 5 H), 6.90 (d, J = 8.8 Hz, 2 H), 6.22 (s, 1 H), 6.18 (d, J = 9.2 Hz, 1 H), 5.81 (s, 1 H), 5.53 (d, J = 9.2 Hz, 1 H), 3.79 (s, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ = 172.8, 168.1, 162.3, 140.5, 137.9, 132.9, 132.2, 129.2, 129.0, 128.8, 128.3, 127.3, 126.7, 126.3, 118.7, 114.4, 59.9, 55.6. HRMS (ESI-TOF): m/z calcd for C₂₄H₂₂N₃O₄S⁺ [M + H]⁺: 448.1326; found: 448.1311. N-{2-[3-(4-Methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-(4-nitrophenyl)prop-2-en-1-yl}benzenesulfonamide (3i) Purified by column chromatography (hexane/EtOAc = 8:2) to give 3i (99 mg, 0.20 mmol, 81%) as a yellow oil. ¹H NMR (250 MHz, CDCl₃): δ = 8.12 (d, J = 8.5 Hz, 2 H), 7.89 (d, J = 8.5 Hz, 2 H), 7.79 (dd, J = 8.2, 1.5 Hz, 2 H), 7.54 (dd, J = 8.2, 6.6 Hz, 3 H), 7.42 (t, J = 7.5 Hz, 2 H), 6.98 (d, J = 8.5 Hz, 2 H), 6.62 (d, J = 9.6 Hz, 1 H), 6.34 (s, 1 H), 5.92 (s, 1 H), 5.70 (d, J = 9.6 Hz, 1 H), 3.88 (s, 2 H). ¹³C NMR (63 MHz, CDCl₃): δ = 172.14, 168.17, 162.49, 147.77, 145.23, 140.26, 133.31, 131.19, 127.79, 127.41, 127.20, 123.99, 118.29, 114.57, 59.65, 55.63. HRMS (ESI-TOF): m/z calcd for C₂₄H₂₁N₄O₆S⁺ [M + H]⁺: 493.1176; found: 493.1188. N-{[1-(4-Bromophenyl)-2-[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]prop-2-en-1-yl}benzenesulfonamide (3m) Purified by column chromatography (hexane/EtOAc = 8:2 to 7:3) to give 3m (103 mg, 0.18 mmol, 93%) as a colorless oil. ¹H NMR (250 MHz, CDCl₃): δ = 7.56–7.43 (m, 3 H), 7.40–7.20 (m, 12 H), 7.18–7.04 (m, 4 H), 6.27–6.13 (m, 2 H), 5.88 (s, 1 H), 5.56 (s, 1 H), 5.49 (d, J = 9.7 Hz, 1 H). ¹³C NMR (63 MHz, CDCl₃): δ = 172.48, 171.29, 140.14, 139.49, 138.98, 136.89, 132.77, 131.70, 131.40, 128.81, 128.76, 128.66, 128.64, 128.59, 128.26, 127.59, 127.42, 126.99, 126.42, 122.10, 59.58, 48.09. HRMS (ESI-TOF): m/z calcd for C₃₀H₂₅BrN₃O₃S⁺ [M + H]⁺: 586.0795; found: 586.0784.
27 Iwabuchi Y, Nakatani M, Yokoyama N, Hatakeyama S. J. Am. Chem. Soc. 1999; 121: 10219 . Reactions were carried out with vinyl-oxadiazole 1a (0.16 mmol), N-sulfonylimine 2a (0.17 mmol), and β-isocupreidine (0.016 mmol)²⁵ as chiral catalyst. So far the best conditions found led to an enantiomeric ratio of 68.5:31.5

Supplementary Material

Supporting Information (PDF)